COLLABORATION AGREEMENT TO CONDUCT A CLINICAL TRIAL AND GRANT AN OPERATING LICENSE BY AND BETWEENCollaboration Agreement • March 16th, 2022 • Synthetic Biologics, Inc. • Pharmaceutical preparations
VCN BIOSCIENCES, S.L., a company duly incorporated under the laws of Spain, having its registered office at Polígon Can Sant Joan, Av. de la Generalitat, nº 152-158, 08174-Sant Cugat del Vallès (Barcelona) (“VCN”); and
LICENSE AGREEMENTLicense Agreement • March 16th, 2022 • Synthetic Biologics, Inc. • Pharmaceutical preparations
IDIBELL and VCN will hereinafter be referred to collectively as the “Parties”, whilst each one of them, individually, shall be referred to as a “Party”.
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • March 16th, 2022 • Synthetic Biologics, Inc. • Pharmaceutical preparations • Michigan
This Asset Purchase Agreement (the “Agreement”) is made and entered into as of the 8th day of November, 2012 by and between SYNTHETIC BIOLOGICS, INC, a Nevada corporation having its principal place of business at 617 Detroit Street, Ann Arbor, Michigan 48104 (“Synthetic” or “Buyer”), and PREV ABR LLC, a Maryland limited liability company having its principal place of business at 7272 Wisconsin Avenue, Suite 300, Bethesda, Maryland 20814 (“Seller”).
TECHNOLOGY TRANSFER AGREEMENTTechnology Transfer Agreement • March 16th, 2022 • Synthetic Biologics, Inc. • Pharmaceutical preparations
As party of the first part, Mr Emilià Pola, of legal age, holder of National ID No. 46.042.576-A, on behalf and in representation of the BELLVITGE BIOMEDICAL RESEARCH INSTITUTE (hereinafter “IDIBELL”), with headquarters at L’Hospitalet de Llobregat (Barcelona), IDIBELL Duran i Reynals, 3a planta, Gran Via de l'Hospitalet, 199, 08907, and with Tax ID Code (Codi d’Identificació Fiscal, CIF) G-58863317. Mr Emilià Pola[***] is acting as Director of IDIBELL, by virtue of the power of attorney granted on 16 September 2008 before the Notary Public of L’Hospitalet de Llobregat, Mr Jorge Farres Reig, under number 1991 of his notarial records.
